1300559-77-6

Basic information

• Product Name: {4-[4-(3-aminopropoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl}acetic acid
• Synonyms: {4-[4-(3-aminopropoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl}acetic acid
• CAS NO: 1300559-77-6
• Molecular Weight: 804.928
• Mol File: 1300559-77-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: {4-[4-(3-aminopropoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl}acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: {4-[4-(3-aminopropoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl}acetic acid(1300559-77-6)
• EPA Substance Registry System: {4-[4-(3-aminopropoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl}acetic acid(1300559-77-6)

Safety Data

• Hazardous Substances Data: 1300559-77-6(Hazardous Substances Data)

Upstream product

• 861065-72-7 [4-(4-methoxy-phenoxy)-3,5-dinitro-phenyl]-acetic acid ethyl ester 
• 83799-60-4 (4-hydroxy-3,5-dinitro-phenyl)-acetic acid ethyl ester 
• 1300857-63-9 C₁₈H₁₇I₄NO₄ 
• 85828-82-6 [3,5-diiodo-4-(4-methoxy-phenoxy)-phenyl]-acetic acid ethyl ester 
• 101588-11-8 C₁₇H₂₀N₂O₄ 
• 1155-40-4 2-(4-(4-hydroxyphenoxy)-3,5-diiodophenyl)acetic acid 
• 67-30-1 tetrac 
• 150-76-5 4-methoxy-phenol 

Relevant articles and documents

Design, synthesis, and biological evaluation of bifunctional thyrointegrin inhibitors: New anti-angiogenesis analogs

Context: Inhibition of pathological angiogenesis. Objective: Obtaining new transactivator, bifunctional, thyroid antagonist, non-toxic anti-angiogenic compounds. Materials and methods: In silico drug design, synthesis in bulk and biological evaluation in chick chorioallantoic membrane (CAM) model. Results: Significant inhibition (range 6573%) at 0.252.0 g/ml doses. Discussion and conclusion: The synthesis of compounds (9), (10), and (11) incorporating long-chain moieties guanidine, urea, methyl amine and, propyl amine substitutions, respectively, into the core molecular framework of tetrac (tetraiodothyroacetic acid) were undertaken. The evaluation of the anti-angiogenic bioactivity of these compounds in the CAM model revealed no loss of activity in comparison with tetrac and XT199, which showed nearly 86% inhibition at dose levels of 1 and 0.5 g/ml, respectively, and validated the concept.